Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CARM Carisma Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CARM
Price (delayed)
$0.5482
Market cap
$22.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.22
Enterprise value
$17.49M
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is
Highlights
The debt has plunged by 69% YoY and by 6% from the previous quarter
The company's EPS rose by 38% YoY and by 16% QoQ
Carisma Therapeutics's quick ratio has plunged by 83% YoY and by 34% from the previous quarter
The equity is down by 31% QoQ
Key stats
What are the main financial stats of CARM
Market
Valuations
Earnings
Shares outstanding
41.79M
Market cap
$22.91M
Enterprise value
$17.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.88
Revenue
$19.96M
Gross profit
$19.96M
Operating income
-$52M
Net income
-$50.77M
EBIT
-$51.27M
EBITDA
-$44.47M
Free cash flow
-$47.14M
Per share
Balance sheet
Liquidity
EPS
-$1.22
EPS diluted
-$1.22
Free cash flow per share
-$1.13
Book value per share
-$0.88
Revenue per share
$0.48
TBVPS
$0.38
Total assets
$15.95M
Total liabilities
$52.62M
Debt
$2.33M
Equity
-$36.66M
Working capital
$3.51M
Debt to equity
-0.06
Current ratio
1.34
Quick ratio
0.74
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
-222.8%
Gross margin
100%
Net margin
-254.3%
Operating margin
-260.5%
Return on assets
-137.4%
Return on equity
N/A
Return on invested capital
-1,452.4%
Return on capital employed
-931.2%
Return on sales
-256.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CARM stock price
How has the Carisma Therapeutics stock price performed over time
Intraday
-9.12%
1 week
194.73%
1 month
184.04%
1 year
-53.15%
YTD
30.9%
QTD
76.84%
Financial performance
How have Carisma Therapeutics's revenue and profit performed over time
Revenue
$19.96M
Gross profit
$19.96M
Operating income
-$52M
Net income
-$50.77M
Gross margin
100%
Net margin
-254.3%
The operating margin has surged by 54% year-on-year and by 18% since the previous quarter
The net margin has soared by 53% YoY and by 17% from the previous quarter
The company's operating income rose by 39% YoY and by 16% QoQ
The net income rose by 37% year-on-year and by 16% since the previous quarter
Price vs fundamentals
How does CARM's price correlate with its fundamentals
Growth
What is Carisma Therapeutics's growth rate over time
Valuation
What is Carisma Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.88
The company's EPS rose by 38% YoY and by 16% QoQ
The equity is down by 31% QoQ
The price to sales (P/S) is 89% lower than the 5-year quarterly average of 10.4 and 28% lower than the last 4 quarters average of 1.6
The company's revenue rose by 32% YoY
Efficiency
How efficient is Carisma Therapeutics business performance
The return on invested capital has dropped by 200% year-on-year and by 54% since the previous quarter
CARM's ROA has dropped by 70% year-on-year and by 17% since the previous quarter
The company's return on sales has surged by 53% YoY and by 17% QoQ
Dividends
What is CARM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CARM.
Financial health
How did Carisma Therapeutics financials performed over time
Carisma Therapeutics's total assets is 70% lower than its total liabilities
Carisma Therapeutics's quick ratio has plunged by 83% YoY and by 34% from the previous quarter
Carisma Therapeutics's total assets has shrunk by 78% YoY and by 48% QoQ
The debt is 106% more than the equity
CARM's debt to equity has shrunk by 109% YoY but it is up by 33% QoQ
The debt has plunged by 69% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.